Blood pressure effects of glucagon-like peptide 1 analogues and sodium glucose transporter 2 inhibitors

Current Opinion in Nephrology and Hypertension

Volumn 23, Issue 5, 2014, Pages 468-472

  Engeli, Stefan ^a   Jordan, Jens ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

blood pressure; body weight; canagliflozin; dapagliflozin; empagliflozin; liraglutide; lixisenatide

Indexed keywords

ANTIHYPERTENSIVE AGENT; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER INHIBITOR; ANTIDIABETIC AGENT; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL;

BLOOD PRESSURE; BLOOD PRESSURE REGULATION; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG MECHANISM; ELECTROLYTE DISTURBANCE; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; REVIEW; SYSTOLIC BLOOD PRESSURE; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTERIAL PRESSURE; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; PATHOPHYSIOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ARTERIAL PRESSURE; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; OBESITY; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2; TREATMENT OUTCOME;

EID: 84906081249     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/01.mnh.0000449846.91046.ac     Document Type: Review

References (40)

1. Wilding JP. The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract 2014; doi: 10.1111/ijcp.12384. [Epub ahead of print].
2. Wilson PW, DAgostino RB, Sullivan L, et al. Overweight and obesity as determinants of cardiovascular risk: The Framingham experience. Arch Intern Med 2002; 162:1867-1872.
3. Labeit AM, Klotsche J, Pieper L, et al. Changes in the prevalence, treatment and control of hypertension in Germany? A clinical-epidemiological study of 50. 000 primary care patients. PLoS One 2012; 7:e52229.
4. Shibao C, Gamboa A, Diedrich A, et al. Autonomic contribution to blood pressure and metabolism in obesity. Hypertension 2007; 49:27-33.
5. Grassi G, Seravalle G, DellOro R, et al. Adrenergic and reflex abnormalities in obesity-related hypertension. Hypertension 2000; 36:538-542.
6. Engeli S, Bö hnke J, Gorzelniak K, et al. Weight loss and the reninangiotensin-Aldosterone system. Hypertension 2005; 45:356-362.
7. Lazo M, Young JH, Brancati FL, et al. NH2-Terminal pro-brain natriuretic peptide and risk of diabetes. Diabetes 2013; 62:3189-3193.
8. Engeli S, Birkenfeld AL, Badin PM, et al. Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. J Clin Invest 2012; 122:4675-4679.
9. Hall ME, do Carmo JM, da Silva AA, et al. Obesity, hypertension, and chronic kidney disease. Int J Nephrol Renovasc Dis 2014; 7:75-88.
10. Foster MC, Hwang SJ, Porter SA, et al. Fatty kidney, hypertension, and chronic kidney disease: The Framingham heart study. Hypertension 2011; 58:784-790.
11. Kim W, Egan JM. The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 2008; 60:470-512.
12. Forst T, Pfü tzner A. Pharmacological profile, efficacy and safety of lixisenatide in type 2 diabetes mellitus. Expert Opin Pharmacother 2013; 14:2281-2296.
13. Katout M, Zhu H, Rutsky J, et al. Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: Results of a systematic meta-Analysis and meta-regression. Am J Hypertens 2014; 27:130-139.
14. Wang B, Zhong J, Lin H, et al. Blood pressure-lowering effects of GLP-1 receptor agonists exenatide and liraglutide: A meta-Analysis of clinical trials. Diabetes Obes Metab 2013; 15:737-749.
15. Robinson LE, Holt TA, Rees K, et al. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: Systematic review and meta-Analysis. BMJ Open 2013; 3:e001986.
16. Nogueiras R, Perez-Tilve D, Veyrat-Durebex C, et al. Direct control of peripheral lipid deposition by CNS GLP-1 receptor signaling is mediated by the sympathetic nervous system and blunted in diet-induced obesity. J Neurosci 2009; 29:5916-5925.
17. Griffioen KJ, Wan R, Okun E, et al. GLP-1 receptor stimulation depresses heart rate variability and inhibits neurotransmission to cardiac vagal neurons. Cardiovasc Res 2011; 89:72-78.
18. Bharucha AE, Charkoudian N, Andrews CN, et al. Effects of glucagon-like peptide-1, yohimbine, and nitrergic modulation on sympathetic and parasympathetic activity in humans. Am J Physiol Regul Integr Comp Physiol 2008; 295:R874-R880.
19. Kim M, Platt MJ, Shibasaki T, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med 2013; 19:567-575.
20. Skov J, Holst JJ, Gøtze JP, et al. Glucagon-like peptide-1: Effect on pro-Atrial natriuretic peptide in healthy males. Endocr Connect 2014; 3:11-16.
21. Fonseca VA, Alvarado-Ruiz R, Raccah D, et al. EFC6018 GetGoal-Mono Study Investigators. Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: A randomized, double-blind, placebocontrolled trial in patients with type 2 diabetes (GetGoal-Mono). Diabetes Care 2012; 35:1225-1231.
22. Kapitza C, Forst T, Coester HV, et al. Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin. Diabetes Obes Metab 2013; 15:642-649.
23. Forst T, Pfü tzner A. Pharmacological profile: Efficacy and safety of lixisenatide in type 2 diabetes mellitus. Expert Opin Pharmacother 2013; 14:2281-2296.
24. Kanai Y, Lee WS, You G, et al. The human kidney low affinity Na+/ glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994; 93:397-404.
25. Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003; 14:2873-2882.
26. Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes 2012; 5:313-327.
27. Washburn WN, Poucher SM. Differentiating sodium-glucose co-Transporter-2 inhibitors in development for the treatment of type 2 diabetes mellitus. Expert Opin Investig Drugs 2013; 22:463-486.
28. Powell DR, DaCosta CM, Gay J, et al. Improved glycemic control in mice lacking Sglt1 and Sglt2. Am J Physiol Endocrinol Metab 2013; 304: E117-E130.
29. Zambrowicz B, Freiman J, Brown PM, et al. LX4211, a dual SGLT1/ SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial. Clin Pharmacol Ther 2012; 92:158-169.
30. Powell DR, Smith M, Greer J, et al. LX4211 increases serum glucagonlike peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose. J Pharmacol Exp Ther 2013; 345:250-259.
31. Turk E, Zabel B, Mundlos S, et al. Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter. Nature 1991; 350:354-356.
32. Oliva RV, Bakris GL. Blood pressure effects of sodium-glucose cotransport 2 (SGLT2) inhibitors. J Am Soc Hypertens 2014; doi: 10.1016/ j.jash.2014.02.003 [Epub ahead of print] First meta-Analyis providing detailed descriptions of cardiovascular effects observed in SGLT2 inhibitor studies
33. Baker WL, Smyth LR, Riche DM, et al. Effects of sodium-glucose cotransporter 2 inhibitors on blood pressure: A systematic review and metaanalysis. J Am Soc Hypertens 2014; 8:262-275.
34. Shah NK, Deeb WE, Choksi R, Epstein BJ. Dapagliflozin: A novel sodiumglucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy 2012; 32:80-94.
35. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial. Lancet 2010; 375:2223-2233.
36. Nauck MA, Del PS, Meier JJ, et al. Dapagliflozin versus glipizide as addon therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: A randomized, 52-week, double-blind, activecontrolled noninferiority trial. Diabetes Care 2011; 34:2015-2022.
37. Bolinder J, Ljunggren O, Kullberg J, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab 2012; 97:1020-1031.
38. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: Diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension 2008; 51:1403-1419.
39. Egan BM, Zhao Y, Axon RN, et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011; 124:1046-1058.
40. Jordan J, Yumuk V, Schlaich M, et al. Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: Obesity and difficult to treat arterial hypertension. J Hypertens 2012; 30:1047-1055.